ENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024
March 21 2024 - 8:00AM
Business Wire
ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of
Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that
the company will report financial results for the three months and
year ended December 31, 2023 on Thursday, March 28, 2024 after the
close of trading on the U.S. financial markets. Management will
host a conference call and webcast beginning at 4:30 p.m. Eastern
time to discuss the results, provide an update on recent corporate
developments and answer questions.
Participants are encouraged to pre-register for the conference
call using this link. Callers who pre-register will receive a
unique PIN to gain immediate access to the call and bypass the live
operator. Participants may register at any time, including up to
and after the start of the call. Those unable to pre-register may
participate by dialing (844) 868-8846 (U.S.) or (412) 317-5465
(International). A webcast of the call can also be accessed at
ENDRA’s Investor Relations page and here.
A telephone replay will be available until April 4, 2024 by
dialing (877) 344-7529 (U.S.) or (412) 317-0088 (International) and
providing the passcode 8041087. A webcast replay will be available
beginning approximately one hour after the completion of the live
conference call here.
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced
UltraSound (TAEUS®), a ground-breaking technology being developed
to visualize tissue like MRI, but at 1/50th the cost and at the
point of patient care. TAEUS® is designed to work in concert with
the more than 700,000 ultrasound systems in use globally today.
TAEUS® is initially focused on the measurement of fat in the liver
as a means to assess and monitor steatotic liver disease (SLD)
(formerly known as NAFLD-NASH), a chronic liver spectrum that
affects over two billion people globally, and for which there are
no practical diagnostic tools. Beyond the liver, ENDRA is exploring
several other clinical applications of TAEUS®, including
visualization of tissue temperature during energy-based surgical
procedures. For more information, please visit
www.endrainc.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240321544727/en/
Company: Irina Pestrikova Senior Director, Finance
investors@endrainc.com www.endrainc.com
Investor Relations: Yvonne Briggs LHA Investor Relations
(310) 691-7100 ybriggs@lhai.com
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
From Oct 2024 to Nov 2024
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
From Nov 2023 to Nov 2024